Observational studyPloS one2026
Prevalence of MASLD and fibrosis in Turkey: Results from a multicenter study of at-risk populations.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05194553 (Identification and Characterization of Non-alcoholic Fatty Liver Disease Among Risk Groups in Turkey), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification and Characterization of Non-alcoholic Fatty Liver Disease Among Risk Groups in Turkey
Who cites it
2 citing papers in PubMed.
- Coronary atherosclerosis across stages of metabolic dysfunction-associated steatotic liver disease: a VCTE-CCTA study.Hepatology international · 2026Article
- TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD).Hepatology forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTurkey represents a high-risk setting for metabolic dysfunction-associated steatotic liver disease (MASLD), with national obesity and diabetes rates of 32% and 15%, respectively. Yet, no prior studies have systematically assessed MASLD and fibrosis prevalence and the independent contribution of these metabolic risk factors in at-risk Turkish populations exhibiting cardiometabolic risks.
methods1,039 adults were enrolled in a multicenter cross-sectional study conducted between 2022 and 2024. All participants presented with at least one of the current MASLD diagnostic criteria. Standardized clinical assessments were performed. Individuals with excessive alcohol consumption (<30 grams/day for men and <20 grams/day for women) were excluded. Steatosis and fibrosis were evaluated using controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) via vibration-controlled transient elastography. MASLD was defined as CAP ≥ 248 dB/m, and significant fibrosis as LSM ≥ 8 kPa. Multivariable logistic regression analyses were used to identify factors associated with MASLD and fibrosis.
resultsThe mean age of the study population was 51.7 ± 13.1 years, and 49.4% were male. The mean body mass index was 30.54 ± 5.85 kg/m2. Obesity and central obesity were seen in 48.5% and 75.1% of the subjects, respectively. MASLD, significant fibrosis (>F2) and advanced fibrosis (>F3) prevalence were 57.5% (95% CI: 54.4%-60.4%), 7.6% (95% CI: 6.1%-9.4%) and 2.6% (95% CI: 1.8%-3.8%) respectively. Multivariable logistic regression of MASLD revealed a significant association with female sex (OR=0. 548; 95% CI: 0.391, 0.770), obesity (OR=2.208; 95% CI: 1.535, 3.177), insulin resistance (OR=2.09; 95% CI: 1.528, 2.881), metabolic syndrome (OR=2.436; 95% CI: 1.614, 3.679) and central obesity (OR=2.816; 95% CI: 1.725, 4.595). Multivariable logistic regression of fibrosis demonstrated a significant association with high income (OR=0.256; 95% CI: 0.069, 0.948), obesity (OR=4.845; 95% CI: 2.540, 9.242), diabetes, (OR=2.172; 95% CI: 1.306, 3.610), insulin resistance OR=4.205; 95% CI: 2.144, 8.246) and metabolic syndrome (OR=2.053; 95% CI: 1.042, 4.045).
conclusionMASLD is prevalent in more than half of the at-risk population studied. Male sex, obesity, metabolic syndrome, insulin resistance and central obesity are significant risk factors associated with it. Despite the high MASLD prevalence, significant fibrosis is less prevalent and is associated with obesity, metabolic syndrome, insulin resistance and diabetes. Further research is warranted in this population. STUDY REGISTRATION: ClinicalTrials.gov, ID: NCT05194553.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.